USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Nov 10, 2021 | Sep 2021 | $-0.77 | $-5.34 | $-3.36 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Nov 10, 2021 | Sep 2021 | $0.00 | $0.00 | $0.00 |
Catabasis Pharmaceuticals's next earnings date is Wednesday, Nov 10, 2021 for the fiscal quarter ending Sep 2021.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 4 | $-0.86 | $-1.26 | $-0.63 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 4 | $-33.61 | $-52.20 | $-22.20 |
| Dec 2022 | 4 | $-3.04 | $-3.90 | $-2.45 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 0 / 0 | $-0.86 | $-0.22 | $-0.28 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 0 / 0 | $-33.61 | $-5.20 | $-6.30 |
| Dec 2022 | 0 / 0 | $-3.04 | $-0.57 | $-0.77 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Dec 2021 | 4 | $0.00 | $0.00 | $0.00 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 4 | $0.00 | $0.00 | $0.00 |
| Dec 2022 | 4 | $0.00 | $0.00 | $0.00 |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Aug 9, 2021 | Jun 2021 | $-1.82 | $-5.34 | -193.41% |
| May 13, 2021 | Mar 2021 | $-0.92 | $-45.60 | -4856.52% |
| Mar 11, 2021 | Dec 2020 | $-2.04 | $-2.64 | -29.41% |
| Nov 12, 2020 | Sep 2020 | $-3.06 | $-3.36 | -9.80% |
| Aug 10, 2020 | Jun 2020 | $-2.73 | $-3.18 | -16.48% |
| May 12, 2020 | Mar 2020 | $-2.46 | $-3.00 | -21.95% |
| Mar 10, 2020 | Dec 2019 | $-3.69 | $-3.30 | 10.57% |
| Nov 7, 2019 | Sep 2019 | $-3.82 | $-3.36 | 12.00% |
| Aug 8, 2019 | Jun 2019 | $-3.64 | $-3.72 | -2.22% |
| May 14, 2019 | Mar 2019 | $-4.17 | $-3.72 | 10.79% |
| Mar 14, 2019 | Dec 2018 | $-5.42 | $-5.10 | 5.87% |
| Nov 13, 2018 | Sep 2018 | $-8.09 | $-4.80 | 40.66% |
| Aug 9, 2018 | Jun 2018 | $-15.90 | $-12.00 | 24.53% |
| May 10, 2018 | Mar 2018 | $-13.50 | $-17.40 | -28.89% |
| Mar 15, 2018 | Dec 2017 | $-18.30 | $-14.40 | 21.31% |
| Nov 9, 2017 | Sep 2017 | $-19.60 | $-18.60 | 5.10% |
| Aug 10, 2017 | Jun 2017 | $-23.40 | $-19.20 | 17.95% |
| May 11, 2017 | Mar 2017 | $-27.20 | $-24.60 | 9.56% |
| Mar 16, 2017 | Dec 2016 | $-29.25 | $-28.20 | 3.59% |
| Nov 10, 2016 | Sep 2016 | $-38.80 | $-32.40 | 16.49% |
| Aug 11, 2016 | Jun 2016 | $-6.40 | $-6.10 | 4.69% |
| May 12, 2016 | Mar 2016 | $-6.40 | $-6.10 | 4.69% |
| Mar 2, 2016 | Dec 2015 | $-7.13 | $-6.30 | 11.68% |
| Nov 12, 2015 | Sep 2015 | $-0.64 | $-0.55 | 14.06% |
| Aug 13, 2015 | Jun 2015 | $-0.71 | $-8.07 | -1036.62% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 11, 2021 | Dec 2020 | $-2.01 | $-12.18 | - |
| Mar 10, 2020 | Dec 2019 | $-2.41 | $-14.10 | - |
| Mar 14, 2019 | Dec 2018 | $-4.93 | $-39.30 | - |
| Mar 15, 2018 | Dec 2017 | $-1.37 | $-76.80 | - |
| Mar 16, 2017 | Dec 2016 | - | $-72.80 | - |
| Mar 2, 2016 | Dec 2015 | - | $-14.92 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Aug 9, 2021 | Jun 2021 | $0.00 | $0.00 | - |
| May 13, 2021 | Mar 2021 | $0.00 | $0.00 | - |
| Mar 11, 2021 | Dec 2020 | $0.00 | $0.00 | - |
| Nov 12, 2020 | Sep 2020 | $0.00 | $0.00 | - |
| Aug 10, 2020 | Jun 2020 | $0.00 | $0.00 | - |
| May 12, 2020 | Mar 2020 | $0.00 | $0.00 | - |
| Mar 10, 2020 | Dec 2019 | $0.00 | $0.00 | - |
| Nov 7, 2019 | Sep 2019 | $0.00 | $0.00 | - |
| Aug 8, 2019 | Jun 2019 | $0.00 | $0.00 | - |
| May 14, 2019 | Mar 2019 | $0.00 | $0.00 | - |
| Mar 14, 2019 | Dec 2018 | $0.00 | $0.00 | - |
| Nov 13, 2018 | Sep 2018 | $0.00 | $0.00 | - |
| Aug 9, 2018 | Jun 2018 | $0.00 | $0.00 | - |
| May 10, 2018 | Mar 2018 | $130.00K | $250.00K | 1.92% |
| Mar 15, 2018 | Dec 2017 | $130.00K | $250.00K | 1.92% |
| Nov 9, 2017 | Sep 2017 | - | $250.00K | - |
| Aug 10, 2017 | Jun 2017 | - | $0.00 | - |
| May 11, 2017 | Mar 2017 | - | $0.00 | - |
| Mar 16, 2017 | Dec 2016 | - | $0.00 | - |
| Nov 10, 2016 | Sep 2016 | - | $0.00 | - |
| Aug 11, 2016 | Jun 2016 | - | $0.00 | - |
| May 12, 2016 | Mar 2016 | - | $0.00 | - |
| Mar 2, 2016 | Dec 2015 | - | $0.00 | - |
| Nov 12, 2015 | Sep 2015 | - | $0.00 | - |
| Aug 13, 2015 | Jun 2015 | - | $0.00 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 11, 2021 | Dec 2020 | $0.00 | $0.00 | - |
| Mar 10, 2020 | Dec 2019 | $0.00 | $0.00 | - |
| Mar 14, 2019 | Dec 2018 | $0.00 | $0.00 | - |
| Mar 15, 2018 | Dec 2017 | $400.00K | $500.00K | 25.00% |
| Mar 16, 2017 | Dec 2016 | - | $0.00 | - |
| Mar 2, 2016 | Dec 2015 | - | $0.00 | - |
CATB's next earnings date is Wednesday, Nov 10, 2021 for the fiscal quarter ending Sep 30, 2021.
According to 4 analysts, the average EPS estimation for Catabasis Pharmaceuticals's next quarterly earnings is $-0.77, with a low EPS estimation of $-1.14, and a high estimation of $-0.64.
Over the last 1 month, EPS estimates have seen 0 upward revisions and 0 downward. The EPS 1 month trend is $-0.77, the last 2 month trend is $-0.15, and the 3 month trend is $-0.20.
Based on 2 analysts, the average revenue estimation is $0.00, with a low revenue estimation of $0.00, and a high estimation of $0.00.
Catabasis Pharmaceuticals's previous earnings date was Aug 9, 2021 for its fiscal quarter ended Jun 30, 2021.
CATB's earnings per share (EPS) was $-5.34, missing the consensus analysts forecast of $-1.82 by -193.41%.
The EPS was higher than the previous fiscal quarter (Mar 2021) by -88.29%, and lower than the same period a year before (Jun 2020) by 67.92%.
Revenues were $0.00.
The company reported a net income of $-7.47M.Free cash flow for the quarter was $-16.14M , compared to $-8.74M last quarter and $-7.49M a year before.
CATB ended the quarter with $655.00K in total debt, a decrease of -25.65% compared to the previous quarter, and a decrease of -51.94% compared to the same quarter a year before.
Catabasis Pharmaceuticals's previous annual earnings date was Mar 11, 2021 for its fiscal year ended Dec 31, 2020.
CATB's earnings per share (EPS) was $-12.18, missing the consensus analysts forecast of $-2.01 by 505.97% , and higher than the previous year's EPS (Dec 2019) by -13.62%.
Revenues were $0.00.
The company reported a net income of $-37.30M.
Catabasis Pharmaceuticals reported a free cash flow of $-32.52M for its fiscal year, compared to $-26.58M a year ago.
The company ended the fiscal year with $1.05M in total debt, a decrease of -53.57% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
